What medications are appropriate for treating severe nausea and vomiting in a 68-year-old patient with end-stage renal disease and a serum creatinine of 10 mg/dL?

Antiemetic Management in ESRD with Severe Nausea and Vomiting

Ondansetron is the first-line antiemetic for severe nausea and vomiting in this 68-year-old ESRD patient with serum creatinine of 10 mg/dL, as it requires no dose adjustment, has superior efficacy compared to metoclopramide in uremic patients, and carries minimal risk of adverse effects in renal failure.

Primary Recommendation: Ondansetron

Use ondansetron 4-8 mg IV/PO every 8 hours as your initial agent 1, 2, 3. This is the safest and most effective choice because:

• No dose adjustment needed in ESRD - ondansetron can be used at standard doses even with creatinine clearance <15 mL/min 4
• Proven superior efficacy - in a head-to-head comparison in uremic patients, ondansetron was approximately twice as effective as metoclopramide (objective score 2.80 vs 1.40, p<0.005; subjective score 4.10 vs 2.10, p<0.005) 2
• Minimal adverse effects - no sedation, no akathisia, and no extrapyramidal symptoms unlike dopamine antagonists 5

Second-Line Options: Dopamine Antagonists

If ondansetron fails to control symptoms, add a dopamine antagonist targeting the chemoreceptor trigger zone, which is particularly relevant in uremia 1, 3, 6:

Haloperidol (Preferred Second-Line)

• Dose: 0.5-2 mg IV/PO every 6-8 hours 1
• No dose adjustment required in ESRD 6
• Effective for uremia-associated nausea 3
• Caution: Monitor for QTc prolongation and extrapyramidal symptoms 6

Metoclopramide (Alternative)

• Dose: 5-10 mg IV/PO every 6-8 hours 1
• Can be used in ESRD but less effective than ondansetron in uremic patients 2
• Major caveat: High risk of akathisia and extrapyramidal symptoms; carries FDA black box warning for tardive dyskinesia 6, 5
• Infuse slowly over 15-30 minutes to reduce akathisia risk 5

Prochlorperazine

• Dose: 5-10 mg IV/PO every 6-8 hours 1
• No specific dose adjustment mentioned for ESRD
• Similar extrapyramidal symptom risk as metoclopramide 5

Agents to AVOID in This Patient

Do NOT use aprepitant (NK1 antagonist) - while it requires no dose adjustment in ESRD 7, there is insufficient evidence for its use in uremia-induced nausea, and it's primarily indicated for chemotherapy-induced nausea 4.

Exercise extreme caution with promethazine - causes excessive sedation and has risk of vascular damage with IV administration 5. Not recommended as first-line.

Clinical Algorithm

1. Start with ondansetron 8 mg IV - reassess after 30-60 minutes
2. If inadequate response: Add haloperidol 0.5-1 mg IV
3. If still refractory: Consider combination therapy with ondansetron + haloperidol + dexamethasone 2-4 mg IV (dexamethasone requires no renal adjustment) 1
4. Monitor for: QTc prolongation (baseline and follow-up ECG if using haloperidol), extrapyramidal symptoms, volume status

Critical Pitfalls to Avoid

• Do not assume all antiemetics are safe in ESRD - many require dose adjustments or are contraindicated 8, 9
• Do not use metoclopramide as first-line - it's inferior to ondansetron in uremic patients and carries higher adverse effect risk 2, 5
• Do not overlook reversible causes - ensure adequate dialysis, check electrolytes (especially calcium, phosphate), rule out uremic pericarditis or gastroparesis 3
• Avoid polypharmacy initially - start with single agent (ondansetron) before layering additional medications 1

Supportive Measures

• Ensure patient is adequately dialyzed if on maintenance dialysis
• Correct electrolyte abnormalities
• Consider small, frequent meals
• Maintain hydration (IV fluids if needed, but cautiously given ESRD)

The evidence strongly supports ondansetron as the safest and most effective initial choice, with dopamine antagonists reserved for refractory cases 1, 2, 3.